ATYR

#5106
aTyr Pharma, Inc. - Common Stock
0.0 1 USD
-98.90%
Setor: Cuidados de saúde
Base: USD
Moeda do lucro: USD
Faixa diária
0.01
0.01
Faixa anual
0.01
1.11
Mudança diária
-98.90%
Mudança mensal
-99.29%
Mudança em 6 meses
-99.44%
Mudança anual
-99.44%
Fechamento anterior
0.4 9
Open
0.0 1
Mínimo
0.0 1
High
0.0 1
Volume
30
Abrir gráfico completo Full chart

Financials

Visão geral Relatórios Estatísticas
Trimestral Ano
Demonstração de resultados Balanço patrimonial Fluxo de caixa
Valor 202020212022202320242025 TTM

aTyr Pharma, Inc. - Common Stock

aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases. The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease, a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients. The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla.